Lexicon Pharmaceuticals Inc (LXRX) - Total Liabilities
Based on the latest financial reports, Lexicon Pharmaceuticals Inc (LXRX) has total liabilities worth $65.96 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Lexicon Pharmaceuticals Inc net asset momentum to track the company's year-over-year net asset growth rate.
Lexicon Pharmaceuticals Inc - Total Liabilities Trend (1999–2025)
This chart illustrates how Lexicon Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does Lexicon Pharmaceuticals Inc generate to measure how efficiently the company converts operating cash flow to free cash.
Lexicon Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Lexicon Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kodiak AI, Inc. Common Stock
NASDAQ:KDK
|
USA | $153.55 Million |
|
Cansino Biologics Inc
SHG:688185
|
China | CN¥-4.93 Billion |
|
PMB Technology Bhd
KLSE:7172
|
Malaysia | RM1.16 Billion |
|
Multi Bintang Indonesia Tbk
JK:MLBI
|
Indonesia | Rp2.01 Trillion |
|
J.Pond Precision Technology Co. Ltd. A
SHE:301326
|
China | CN¥1.24 Billion |
|
Shanxi Guoxin Energy Co Ltd A
SHG:600617
|
China | CN¥20.60 Billion |
|
Sunrise Group Co Ltd
SHE:002752
|
China | CN¥4.15 Billion |
|
Bumi Resources Minerals Tbk
JK:BRMS
|
Indonesia | Rp185.57 Million |
Liability Composition Analysis (1999–2025)
This chart breaks down Lexicon Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Lexicon Pharmaceuticals Inc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 18.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lexicon Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lexicon Pharmaceuticals Inc (1999–2025)
The table below shows the annual total liabilities of Lexicon Pharmaceuticals Inc from 1999 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $77.45 Million | -49.20% |
| 2024-12-31 | $152.47 Million | +11.85% |
| 2023-12-31 | $136.32 Million | +76.64% |
| 2022-12-31 | $77.17 Million | +231.02% |
| 2021-12-31 | $23.31 Million | -50.83% |
| 2020-12-31 | $47.42 Million | -84.23% |
| 2019-12-31 | $300.61 Million | -3.20% |
| 2018-12-31 | $310.54 Million | -19.22% |
| 2017-12-31 | $384.44 Million | +20.81% |
| 2016-12-31 | $318.22 Million | -13.76% |
| 2015-12-31 | $368.98 Million | +96.94% |
| 2014-12-31 | $187.36 Million | +80.16% |
| 2013-12-31 | $104.00 Million | -1.05% |
| 2012-12-31 | $105.10 Million | -20.94% |
| 2011-12-31 | $132.94 Million | +10.92% |
| 2010-12-31 | $119.86 Million | +27.15% |
| 2009-12-31 | $94.26 Million | +43.52% |
| 2008-12-31 | $65.68 Million | -20.60% |
| 2007-12-31 | $82.72 Million | -21.04% |
| 2006-12-31 | $104.77 Million | -21.18% |
| 2005-12-31 | $132.91 Million | +47.05% |
| 2004-12-31 | $90.39 Million | -23.39% |
| 2003-12-31 | $117.98 Million | +270.20% |
| 2002-12-31 | $31.87 Million | +47.42% |
| 2001-12-31 | $21.62 Million | +65.47% |
| 2000-12-31 | $13.06 Million | -7.34% |
| 1999-12-31 | $14.10 Million | -- |
About Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercialize… Read more